CARDIOVASCULAR JOURNAL OF AFRICA • Vol 21, No 5, September/October 2010
AFRICA
285
Am J Clin Nutr
2006;
83
: 1097–1105.
58. Myung K, Narciso JA, Manthey JA. Removal of furanocoumarins
in grapefruit juice by edible fungi.
J Agric Food Chem
20008:
56
:
12064–12068.
59. Uesawa Y, Mohri K. The use of heat treatment to eliminate drug
interactions due to grapefruit juice.
Biol Pharm Bull
2006;
29
(110);
2274–2278.
60. Uesawa Y, Mohri K. UV-irradiated grapefruit juice loses pharmacoki-
netic interaction with nifedipine in rats.
Biol Pharm Bull
2006;
29
(6):
1286–1289.
61. Owira PMO, Ojewole JAO. Grapefruit juice improves glycemic control
but exacerbates metformin-induced lactic acidosis in non-diabetic rats:
Meth Findings Exper Clin Pharmacol
2009;
31
(9): 563–570.
62. Fimognari FL, Pastorelli R, Incalzi RA. Phenformin-induced lactic
acidosis in an older diabetic patient: a recurrent drama (phenformin and
lactic acidosis).
Diabetes Care
2006;
29
(4): 950–951.
63. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfat C.
Definition of metabolic syndrome: Report of the National Heart, Lung
and Blood Institute/American Heart Association conference on scien-
tific issues related to definition.
Circulation
2004;
109
(3): 433–438.
64. Florida Department of citrus:
History of Dieting.
Florida: Department of
Citrus, Lakeland FL, 2003.
65. Fujioka K. Greenway F, Sheard J, Ying Y. The effects of grapefruit juice
on weight and insulin resistance: relationship to metabolic syndrome.
J
Med Food
2006;
9
(1): 49–54.
66. Adeneye AA. Hypoglycemic and hypolipidemic effects of methanol
seed extract of Citrus paradisi Macfad (Rutaceae) in alloxan-induced
diabetic Wistar rats.
Nig Q J Hosp Med
2008;
18
(4): 211–215.
67. Graf BA, Milbury PE, Blumberg JB. Flavonols, flavones, flavanones,
and human health: epidemiological evidence.
J Med Food
2005;
8
(3):
281–290.
68. Allister EM, Borradaile NM, Edwards JY, Huff MW. Inhibition of
microsomal triglyceride transfer protein expression and apolipoprotein
B100 secretion by the citrus flavonoid naringenin and by insulin involves
activation of the mitogen-activated protein kinase pathway in hepato-
cytes.
Diabetes
2005;
54
(6): 1676–1683.
69. Punithavathi VR, Anuthama R, Prince PS. Combined treatment with
naringin and vitamin C ameliorates streptozotocin-induced diabetes in
male Wistar rats.
J Appl Toxicol
2008;
28
(6): 806–813.
70. Jung UJ, Lee MK, Jeong KS, Choi MS
.
Hypoglycemic effects of hespe-
ridin and naringin are partly mediated by hepatic glucose-regulating
enzymes in C57BL/KsJ-db/db mice.
J Nutr
2004;
134
: 2499–2503.
71. Jung UJ, Lee MK, Park YB, Kang MA, Choi MS. Effect of citrus
flavonoids on lipid metabolism and glucose-regulating enzyme mRNA
levels in type-2 diabetic mice.
Int J Biochem Cell Biol
2006;
38
(7):
1134–1145.
72. Owira PMO. Grapefruit juice improves glycemic index and up-regulates
expression of organic cation transporter protein (OCT1) in the rat. PhD
thesis, 2009. University of KwaZulu-Natal.
73. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M,
et al
.
Identification and characterisation of a small molecule AMPK activator
that treats that treats key components of type2 diabetes and metabolic
syndrome.
Cell Metab
2006;
3
: 403–416.
74. Seol W, Choi SH Moore DD. An orphan nuclear hormone receptor that
lacks DNA binding domain and heterodimerises with other receptors.
Science
1996;
272
: 1336–1339.
75. Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida
J, Fukamizu A. Bile acids regulate gluconeogenic gene expression via
small heterodimer partner-mediated repression of hepatocyte nuclear
factor 4 amd Foxo1.
J Biol Chem
2004;
279
: 23158–23165.
76. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes
and the metabolic syndrome.
Cell Metab
2009;
9
(5): 407–416.
77. Mursu J, Voutilainen S, Nurmi T, Tuomainen TP, Kurl S, Salonen JT.
Lavonoid intake and the risk of ischaemic stroke and CVD mortality
in middle-aged Finnish men: the Kuopio Ischaemic Heart Disease Risk
Factor Study.
Br J Nutr
2008;
100
(4): 890–895.
78. Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP, Nettleton JA,
et al
. Flavonoid intake and cardiovascular disease mortality: a prospec-
tive study in postmenopausal women.
Am J Clin Nutr
2007;
85
(3):
895–909.
79. Benavente-García O, Castillo J. Update on uses and properties of citrus
flavonoids: new findings in anticancer, cardiovascular, and anti-inflam-
matory activity.
J Agric Food Chem
2008;
56
(15): 6185–6205.
80. Borradaile NM, de Dreu LE, Huff MW. Inhibition of net HepG2
cell apolipoprotein B secretion by the citrus flavonoid naringenin
involves activation of phosphatidylinositol 3-kinase, independent of
insulin receptor substrate-1 phosphorylation.
Diabetes
2003;
52
(10):
2554–2561.
81. Monforte MT, Trovato A, Kirjavainen S, Forestieri AM, Galati EM, Lo
Curto RB. Biological effects of hesperidin, a
Citrus
flavonoid. (note
II): hypolipidemic activity on experimental hypercholesterolemia in rat.
Farmaco
1995;
50
(9): 595–599.
82. Orallo F, Alvarez E, Basaran H, Lugnier C. Comparative study of the
vasorelaxant activity, superoxide-scavenging ability and cyclic nucle-
otide phosphodiesterase-inhibitory effects of hesperetin and hesperidin.
Naunyn Schmiedebergs Arch Pharmacol
2004;
370
(6): 452–463.
83. Orallo F, Camiña M, Alvarez E, Basaran H, Lugnier C. Implication of
cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activ-
ity of the citrus-fruits flavonoid (+/–)-naringenin.
Planta Med
2005;
71
(2): 99–107.
84. Yamamoto M, Suzuki A, Hase T. Short-term effects of glucosyl hespe-
ridin and hesperetin on blood pressure and vascular endothelial function
in spontaneously hypertensive rats.
J Nutr Sci Vitaminol (Tokyo)
2008;
54
(1): 95–98.
85. Yamamoto M, Suzuki A, Jokura H, Yamamoto N, Hase T. Glucosyl
hesperidin prevents endothelial dysfunction and oxidative stress in spon-
taneously hypertensive rats.
Nutrition
2008;
24
(5): 470–476.
86. Rajadurai M, Prince PS. Preventive effect of naringin on cardiac mito-
chondrial enzymes during isoproterenol-induced myocardial infarction
in rats: a transmission electron microscopic study.
J Biochem Mol
Toxicol
2007;
21
(6): 354–361.
87. Rajadurai M, Prince PS. Naringin ameliorates mitochondrial lipid
peroxides, antioxidants and lipids in isoproterenol-induced myocardial
infarction in Wistar rats.
Phytother Res
2009;
23
(3): 358–362.
88. Zitron E, Scholz E, Owen RW, Lück S, Kiesecker C, Thomas D,
et al
.
QTc prolongation by grapefruit juice and its potential pharmacological
basis: HERG channel blockade by flavonoids.
Circulation
2005;
111
(7):
835–838.
89. Piccirillo G, Magrì D, Matera S, Magnanti M, Pasquazzi E, Schifano E,
et al.
Effects of pink grapefruit juice on QT variability in patients with
dilated or hypertensive cardiomyopathy and in healthy subjects.
Transl
Res
2008;
151
(5): 267–272.
90. Lin C, Ke X, Ranade V, Somberg J. The additive effects of the active
component of grapefruit juice (naringenin) and antiarrhythmic drugs on
HERG inhibition.
Cardiology
2008;
110
(3): 145–152.
91. Solskov L, Løfgren B, Kristiansen SB, Jessen N, Pold R, Nielsen TT,
et al
. Metformin induces cardioprotection against ischaemia/reper-
fusion injury in the rat heart 24 hours after administration.
Basic Clin
Pharmacol Toxicol
2008;
103
(1): 82–87.
